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Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) has emerged as a powerful metabolic regulator in diverse tissues includ-
ing fat, skeletal muscle, and the heart. It is now established that activation of PPARβ/δ promotes fatty acid oxidation in several
tissues, such as skeletal muscle and adipose tissue. In muscle, PPARβ/δ appears to act as a central regulator of fatty acid catabolism.
PPARβ/δ contents are increased in muscle during physiological situations such as physical exercise or long-term fasting, character-
ized by increased fatty acid oxidation. Targeted expression of an activated form of PPARβ/δ in skeletal muscle induces a switch to
form increased numbers of type I muscle ﬁbers resembling the ﬁber type transition by endurance training. Activation of PPARβ/δ
also enhances mitochondrial capacity and fat oxidation in the skeletal muscle that resembles the eﬀect of regular exercise. There-
fore, it is hypothesized that muscle-speciﬁc PPARβ/δ agonists could be a key strategy to support the poor cardiorespiratory ﬁtness
associated with metabolic disorders.
Copyright © 2007 Adnan Erol. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptor β/δ (PPARβ/δ)
has emerged as a powerful metabolic regulator in diverse tis-
sues including fat, skeletal muscle, and the heart. It is now
established that activation of PPARβ/δ promotes fatty acid
oxidation in several tissues, such as skeletal muscle and adi-
pose tissue. In muscle, PPARβ/δ appears to act as a cen-
tral regulator of fatty acid catabolism. PPARβ/δ contents are
increased in muscle during physiological situations such as
physical exercise or long-term fasting, characterized by in-
creasedfattyacidoxidation[1].Targetedexpressionofanac-
tivated form of PPARβ/δ in skeletal muscle induces a switch
toformincreasednumbersoftypeImuscleﬁbersresembling
the ﬁber type transition by endurance training [2]. Activa-
tion of PPARβ/δ also enhances mitochondrial capacity and
fat oxidation in the skeletal muscle that resembles the ef-
fect of regular exercise [2]. These raise a parallel question of
whether PPARβ/δ agonists, as with constitutive genetic acti-
vation of PPARβ/δ in skeletal muscle, can drive the forma-
tion of oxidative myoﬁbers and enhance physical activity en-
durance [3].
The beneﬁcial eﬀect of exercise on cardiovascular ﬁt-
ness has proven particularly successful as a treatment for the
metabolic diseases, including type 2 diabetes [4]. Regular ex-
ercise has been shown to induce changes in both skeletal
muscle metabolism and muscle ﬁber type over time, most
notably an increase in mitochondrial content and oxida-
tive metabolism as well as a shift toward a more slow ox-
idative ﬁber type [5]. Exercise-related adjustments in fuel
homeostasis and ﬁber type changes are mediated not only
by an increase in mitochondrial number but also by func-
tional changes in the resident mitochondrial population [6].
Six weeks of running endurance training in human skeletal
muscle reasoned in a shift toward an increased type I muscle
ﬁber phenotype, which supports the results of mice experi-
ments [7].
Skeletal muscle is a major player in glucose homeostasis
under basal conditions and in response to insulin and exer-
cise.Therefore,skeletalmusclemustbeconsideredanimpor-
tant therapeutic target tissue in the battle against cardiovas-
cular disease. Cardiovascular risk factors are directly inﬂu-
enced by diet, metabolism, and physical activity. Metabolism
and physical activity, in turn, are primarily driven by skeletal
muscle [8]. However, the type of fuels, style of activity, and2 PPAR Research
neuronal innervations aﬀect muscle energy metabolism. In
fact,musclemassisnottheonlydeterminantofmusclefunc-
tion, and aerobic exercise training may import positive ef-
fects on neuromuscular adaptations and, consequently, mus-
cle quality especially in individuals who were sedentary and
sarcopenic prior to the exercise intervention [9]. Emerging
evidence suggests that skeletal muscle stimulated changes in
energyhomeostasisreasoningeneexpressionandcontribute
to muscle plasticity. A number of energy-sensing molecules
have been shown to sense the variations in energy homeosta-
sis. These molecules may therefore sense information relat-
ing to the intensity, duration, and the frequency of muscle
exercise [10]. Muscular activity acts as a powerful stimulus
for the hypothalamic-pituitary axis, leading to the liberation
ofseveralneuroendocrinehormones,whichareaccuratereg-
ulators of fuel homeostasis [11].
Human skeletal muscle may appear to be homogenous,
but in fact it is composed of distinct ﬁber types, referred as
slow and fast, deﬁned by the myosin isotype expressed in the
particular ﬁber. Slow muscle ﬁber expresses type I myosin;
fast ﬁbers can express types IIa, IIb, and IIx. The variety in
ﬁber type enables the person to perform diﬀerent types of
work. Given the high degree of skeletal muscle plasticity in
humans with exercise, it is likely that the contraction func-
tion of slow-twitch and fast-twitch muscle ﬁbers undergo
diﬀerentialalterationswithdistancerunningtraining[8].In-
terventions including endurance exercise, physical inactivity,
and metabolic diseases such as type 2 diabetes mellitus can
induce the transdiﬀerentiation of myoﬁbers [12].
Skeletal muscle ﬁbers are classiﬁed by two major func-
tional characteristics: speed of contraction, and the aero-
bic(oxidative)/anaerobic(glycolytic)productionofATP.The
speed of the ﬁber reﬂects how fast the ﬁber hydrolyses ATP
[13]. Fast ﬁbers (type IIb or white ﬁbers) utilize anaerobic
glycolysis, are low in mitochondria and myoglobin and rich
in glycogen, and are suited to short-term intense activity.
Slow ﬁbers (type I or red ﬁbers) utilize aerobic metabolism
andare suitedtoendurance activity. Thereis anintermediate
fastﬁberstypeIIathatcombinefast-twitchcapacitywithaer-
obic fatigue resistant metabolism and intermediate glycogen
levels [13]. In general, the metabolic characteristics of type
IIb ﬁbers include a reduced oxidative enzyme activity and an
increased glycolytic enzyme activity in comparison with type
I muscle ﬁbers (oxidative slow-twitch) or type IIa (oxidative
fast-twitch) [14]. Moreover, it has been postulated, mostly
based on animal studies, that muscle ﬁbers follow an order
of type I > type IIa > type IIb for insulin sensitivity [15].
One of the genes induced in skeletal muscle after exercise
is the peroxisome proliferator-activated receptor (PPAR)-γ
coactivator-1α (PGC-1α). PGC-1α,ac o a c t i v a t o ro fs e v e r a l
nuclear receptors and other transcription factors, has been
shown to be involved in the regulation of mitochondrial
biogenesis, adaptive thermogenesis, and enzymes involved
in fatty acid oxidation [16]. It is now well established that
PGC1αinducesaremodelingofskeletalmuscleﬁbercompo-
sition toward more oxidative type I ﬁbers. The expression of
PGC1α in skeletal muscle is readily inducible by both short-
term exercise and endurance training in animal models and
human [17]. In human skeletal muscle, endurance training
induces an increase in PGC1α, particularly in type IIa ﬁbers.
This means that when type IIa ﬁbers are properly activated,
they promote mitochondrial biogenesis and the switch of
musclestoatypeIphenotype[7].However,PGC1αhasbeen
shown to inhibit the insulin signaling pathway in the liver,
and increased hepatic PGC1α expression could be expected
to stimulate hepatic glucose output contributing to the hy-
perglycemic state [18]. Furthermore, PGC1α expression has
been reported to be increased in liver of both type 1 and type
2 diabetic mouse models [19].
As mentioned above, PGC1α is a master regulator of mi-
tochondrial biogenesis. Peroxisome proliferator response el-
ement (PPRE) in the distal region of PGC1α binds PPARβ/δ.
Consequently, activation of PPARβ/δ,b u tn o tP P A R α, in-
duces transcription of the PGC1α gene in muscle [20]. In
contrast, it has been reported that in transgenic mice over-
expressing PPARβ/δ [2, 21], and in rats in which PPARβ/δ
activity is increased by raising plasma fatty acids [22], mi-
tochondrial biogenesis is augmented without an increase in
PGC1α expression.
Still unanswered question is whether PGC1α activation
alone,intheabsenceofexercise,wouldbesuﬃcienttoconfer
protection against diabetes or not. Although muscle-speciﬁc
overexpresion of PGC1α in transgenic mice results in mito-
chondrial proliferation and increased expression of genes in-
volved in oxidative phosphorylation, the impact of this ma-
nipulation on whole body glucose homeostasis has not been
reported [5].
2. PPARs: LIPID SENSORS AND
TRANSCRIPTIONAL SWITCHES
Metabolism, in part, is regulated by nuclear receptors. Essen-
tially, these receptors function as the conduit between en-
vironmental stimuli and gene expression, and mediate the
physiological response [23]. PPARsare a subgroup of the nu-
clear receptor superfamily of ligand-inducible transcription
factors [23]. They form heterodimers with retinoid X recep-
tors (RXRs) and bind to consensus DNA sites. In the absence
of ligand, PPAR-RXR heterodimers recruit corepressors and
associated some other modifying factors and silence tran-
scription. Ligand binding induces a conformational change
in PPAR-RXR complexes, releasing repressors in exchange
for coactivators. Unlike classical endocrine receptors that
bind to high-aﬃnity glandular hormones, ligand-activated
PPARs turn on feed-forward metabolic cascades to regu-
late lipid homeostasis via the transcription of genes involved
in lipid metabolism, storage, and transport. Additionally,
PPARs may suppress inﬂammation through the stabilization
of repressive complexes at inﬂammatory gene promoters [3].
Three PPAR isotypes, α, β or δ,a n dγ,h a v eb e e nd e t e r -
mined so far in mammalian. PPARs act as nutritional lipid
sensors and control transcriptional rate of a large panel of
genes implicated in organogenesis, cell proliferation, cell dif-
ferentiation, inﬂammation, and metabolism of lipid or car-
bohydrates [24, 25]. PPARα and PPARγ are the most exten-
sively examined because they are involved in the eﬀects of
marketed compounds with pharmaceutical interest [25].Adnan Erol 3
Fatty acid catabolism is very active in muscle and uti-
lization of lipids is enhanced in physiological situations
such as fasting and physical exercise [25]. PPARα is known
regulator of fatty acid oxidation gene expression. PPARα-
speciﬁc agonists stimulate mitochondrial β-oxidation. How-
ever, PPARα knock-out mice exhibited minimal alteration in
skeletalmusclefattyacidoxidativecapacity[26].Severallines
of evidence have established that PPARβ/δ, which is the pre-
dominantisotypeexpressedinskeletalmuscle,playsacentral
role in the control of lipid metabolism of this tissue [1, 25].
This high abundance of PPARβ/δ may compensate for the
lack of PPARα in the knock-out mice [25, 26].
Clear improvements in skeletal muscle metabolism me-
diated by nuclear receptor function and pharmacological
activation will promote improved carbohydrate and lipid
metabolism in skeletal muscle because numerous metabolic
genes regulated by nuclear receptors have been identiﬁed
ranging from transport molecules, enzymes involves in lipid
and carbohydrate metabolism, lipid and carbohydrate stor-
age, thermogenesis, and signaling pathways [23, 24]. Hence,
skeletal muscle has a paramount role in energy balance,
and is the primary tissue of insulin-stimulated glucose up-
take, disposal, and storage, regulates cholesterol eﬄux, and
strongly inﬂuences metabolism via modulation of circulat-
ing and stored lipid ﬂux. For example, lipid catabolism sup-
pliesupto70%oftheenergyrequirementsforrestingmuscle
[13].
PPARβ/δ agonistshaveasigniﬁcantroleintheregulation
of the mRNAs encoding the uncoupling proteins (UCPs),
mitochondrial proton carriers, which control metabolic ef-
ﬁciency, energy expenditure, and adaptation to nutrient (i.e.,
preferential lipid utilization and thermogenesis by uncou-
pling oxidation/respiration from ATP synthesis) [27].
3. IMPORTANCE OF PPARβ/δ IN MUSCLE
Unlike in liver and heart, PPARβ/δ is expressed in skele-
tal muscle at 10- and 50-fold higher levels compared with
PPARαandPPARγ,respectively,anditispreferentiallyfound
in oxidative rather than glycolytic myoﬁbers [28].
Mice in which PPARβ/δ is selectively ablated in skeletal
muscle myocytes exhibited a muscle ﬁber-type switching to-
wardloweroxidativecapacitythatprecededthedevelopment
of obesity and diabetes, thus demonstrating that PPARβ/δ is
instrumental in myocytes to maintenance of oxidative ﬁber-
type switching is likely to be the cause and not the conse-
quence of these metabolic disorders. As mentioned previ-
ously, the eﬀect of PPARβ/δ on the formation and/or main-
tenance of slow muscle ﬁbers can be ascribed, at least in part,
tothestimulationofPGC1αexpressionatthetranscriptional
level [29].
How might endogenous PPARβ/δ become activated nat-
urally by exercise training? It is possible that exercise gener-
ates or increases endogenous ligands for PPARβ/δ.E x e r c i s e -
induced abundance of fatty acids and their metabolites can
activatePPARβ/δ.Inaddition,exercisemaystimulateexpres-
sion of PGC1α and thereby activate PPARβ/δ.P G C 1 α physi-
cally associates with PPARβ/δ in muscle tissue and can pow-
erfully activate it even in the absence of ligands [30].
With aging, two conceptually diﬀerent kinds of muscular
atrophy, acute and chronic, can occur. Acute atrophy is as-
sociated with disuse; and chronic atrophy is more typically
associated with aging [31]. The number of muscle ﬁbers of
both types I and II decreased signiﬁcantly after 60 years of
age. Decrease in weight of the muscle with age was slight and
not signiﬁcant, being considered to be due to the increase in
s i z eo ft y p eIﬁ b e r sa f t e r6 0y e a r so fa g e .T h el o s so fﬁ b e r s
begins early, at 25 years, and thereafter accelerates. Total vol-
umeofmuscleﬁbersoftypeIdidnotdecreasewithage.Age-
related loss of skeletal muscle is associated with a selective
atrophy of the type II ﬁbers [32].
The greater age-related mitochondrial dysfunction in
muscles with high type II content provides insight into the
preferential loss of type II ﬁbers with age [33]. The tempo
of mitochondrial dysfunction varies among muscles and in
proportion to type II muscle ﬁber content, suggesting that
intracellular factors, rather than time alone, may play an im-
portant role in mitochondrial aging. These defects have im-
portant impact on cell fate resulting in sarcopenia, which is a
leading cause of disability in the elderly. Mitochondrial dys-
function may be an inevitable part of aging; however, in con-
trast to the conventional thinking that the defects are per-
manent, research outcomes show that at least part of this
dysfunction is reversible with endurance training in human
muscle [34].
Skeletal muscle must perform diﬀerent kind of work,
and distinct ﬁber types have evolved to accommodate these
activities [35]. PGC1β, the structural homologue closest to
PGC1α, is encoded by a separate gene and displays a simi-
lar tissue distribution. The role played by PGC1β is not well
understood.However,PGC1β expressionwasfoundtobere-
lated to fat oxidation and nonoxidative glucose metabolism.
Insulin increases and aging reduces skeletal muscle PGC1α
and PGC1β levels. PGC1β expression is reduced in mus-
cle of healthy elderly individuals and in patients with type
2 diabetes [36]. Transgenic expression of PGC1β causes a
marked induction of type IIx ﬁbers, which are oxidative but
have “fast-twitch” biophysical properties [35]. In contrast to
PGC1α,P G C 1 β seems not to activate nuclear receptors [37].
Therefore,pharmacologicactivationofPGC1β isexpectedto
decrease the age-associated progressivefast-twitch atrophy in
addition to its antiobese and antidiabetic functions.
A reduced oxidative enzyme capacity of skeletal muscle
has been found in type 2 diabetes as well as in obesity that is
not complicated by diabetes. Although a full explanation for
these diﬀerences in glycolytic and oxidative enzyme activities
in skeletal muscle in obesity and type 2 diabetes compared
with lean individuals has not been determined, one possi-
bility is an altered proportion of muscle ﬁber types [38]. An
increased proportion of type IIb muscle ﬁbers, also termed
glycolytic fast-twitch ﬁbers, has been reported in type 2 dia-
betes in several studies [15] .I nar e c e n ts t u d y ,i nt h ew h o l e
muscle, oxidative activity was decreased in patients with type
2 diabetes. The slow oxidative ﬁber fraction was reduced by
16%, whereas the fast glycolytic ﬁber fraction was increased
by 49% in skeletal muscle from the diabetic patients [38].
RecentevidencehasdemonstratedactivationofPPARβ/δ
in the major mass peripheral tissue (i.e., adipose and the4 PPAR Research
skeletal muscle). It enhances glucose tolerance, insulin-
stimulated glucose disposal, lipid catabolism, energy expen-
diture, cholesterol eﬄux, and oxygen consumption. These
eﬀects positively inﬂuence the blood-lipid proﬁle. Further-
more, PPARβ/δ- a c t i v a t e dt y p eIm u s c l eﬁ b e ra b u n d a n c e
leads to increased endurance, insulin sensitivity, and resis-
tance to obesity. Thus PPARβ/δ has rapidly emerged as a po-
tential target in the battle against dyslipidemia, insulin resis-
tance, type 2 diabetes, and obesity with therapeutic eﬃcacy
in the treatment of cardiovascular disease risk factors [39].
In addition to eﬀects on muscle composition and
metabolic capability, muscle-speciﬁc PPARβ/δ overexpres-
sion also aﬀects adipose tissue mass. Most probably, the
metabolic ﬂux toward muscle is increasing in mice overex-
pressing PPARβ/δ, reducing fatty acid supply for triglyceride
storage in adipose tissue. Muscle-speciﬁc PPARβ/δ overex-
pression promoted a shift toward smaller adipocyte size.
Such a diﬀerence in cell size could account for the secretion
of more adipokines such as adiponectin increase insulin sen-
sitivity [21].
Metabolic and ﬁber type regulation of skeletal muscle
by PPARβ/δ has several physiological implications. First, the
presence of an increased proportion of oxidative slow-twitch
ﬁbers is predicted to decrease skeletal muscle fatigability. In-
creased endurance in marathon runners is linked to a higher
proportion of oxidative slow-twitch ﬁbers in their skeletal
muscles. Second, oxidative ﬁbers have a tremendous impact
on fatty acid homeostasis. As it was clearly explained above,
both obesity and insulin resistance are linked to a decrease
in the proportion of oxidative slow-twitch ﬁbers in skeletal
muscle [3].
4. PPARβ/δ ACTION IN CARDIOMYOCYTES
In contrast to PPARγ ligands where some controversy exists,
administration of PPARβ/δ ligands is thought to be protec-
tive against cardiomyopathy. Impaired fatty acid oxidation
andashifttorelianceonglucosemetabolismarehallmarksof
myocardial diseases such as cardiac hypertrophy and conges-
tive heart failure. It was shown that cardiomyocyte-speciﬁc
deletion of PPARβ/δ suppresses the expression of oxida-
tive genes leading to impaired fatty acid oxidation and re-
ciprocal increase in glucose oxidation, along with fat ac-
cumulation in cardiomyocytes. These alterations lead to
progressive myocardial lipid accumulation, cardiac hyper-
trophy, and congestive heart failure with reduced survival
[40].Inculturedneonatalratventricularcardiomyocytes,se-
lective PPARβ/δ activation inhibits phenylephrine-induced
cardiomyocyte hypertrophy and lipopolysaccharide-induced
nuclear factor(NF)-κBactivationthatmaybetheunderlying
mechanism responsible for the inhibition of cardiomyocyte
growth [41].
PPARβ/δ-dependent maintenance of basal fatty acid ox-
idation is crucial for normal cardiac mechanics. Indeed,
mice with cardiac-speciﬁc deletion of PPARβ/δ develop age-
dependent cardiac lipotoxicity, cardiac hypertrophy, end-
stage dilated cardiomyopathy, and decreased survival [3].
Exercise
PPARβ/δ
Skeletal muscle
Natural agonists
Speciﬁc
synthetic
agonist for
PPARβ/δ
Oxidative metabolism:
• Fatty acid uptake
• Fatty acid oxidation
• Mitochondrial biogenesis
• Type 1 muscle ﬁbers
• Exercise endurance
Figure 1: Diﬀerent type of activators such as exercise and natural
ligands but particularly speciﬁc synthetic agent activates PPARβ/δ
in skeletal muscle and strengthens the mitochondrial apparatus and
potential to oxidize lipids. More fatty acids are pulled into the more
oxidative ﬁber made by the inﬂuence of speciﬁc agonist. Hence,
PPARβ/δ-induced improvements in oxidative capacity and fat uti-
lization in skeletal muscle could lead to metabolic improvements.
5. PPARβ/δ AND METABOLIC SYNDROME
It was suggested that the physiological role of PPARβ/δ may
be a direct switch from glucose metabolism to fatty acid
metabolism. It is conceivable that free fatty acids released
from adipose tissues on fasting or exercise provide PPARβ/δ
ligands to stimulate fatty acid oxidation and thermogenesis
in skeletal muscle [42]. Furthermore, transgenic expression
of activated PPARβ/δ in adipocytes leads to a lean pheno-
type and prevents high-fat diet-induced obesity in mice by
increasing energy expenditure and fat oxidation. These ef-
fects appear to be due to increased thermogenesis and fat
oxidation as a result of induction of UCP1 expression, and
increased expression of mitochondrial enzymes of fatty acid
oxidation in white adipose tissue [30].
Recent studies have reported that activation of PPARβ/δ
alleviatesdyslipidemia,hyperglycemia,andinsulinresistance
inanimalmodelsofobesityandtype2diabetes[43,44].Fur-
thermore,PPARβ/δ agonisttreatmentpreventedweightgain,
and decreased levels of serum glucose, insulin, and lipids in
rats fed a high-fat diet. In addition, PPARβ/δ agonist in-
creasedexpressionofvisfatin,adiponectin, anddecreasedre-
sistin expression in both rats fed a high-fat diet and cultured
3T3-L1 adipocytes [44].
PPARβ/δ is involved in the regulation of genes partici-
pating in lipid and lipoprotein metabolism as well as in adi-
pose tissue and muscle fatty acid oxidation. However, an in-
crease in HDL-cholesterol is the predominant consequence
of PPARβ/δ activation [45].
These data provide evidence that the activation of
PPARβ/δ have an independent and additive impact on the
eﬀectiveness of aerobic physical exercise and insulin sensitiv-
ity. Provided that a number of potential adverse side-eﬀects
could be managed, high-aﬃnity PPARβ/δ synthetic ligands
wouldclearlybeusefuldrugsofthefuturetoeﬀectivelytargetAdnan Erol 5
some of the most important abnormalities associated with
the metabolic syndrome such as insulin resistance, hyper-
glycemia, and dyslipidemia [46].
6. ADVERSE EFFECTS OF PPARβ/δ ACTIVATION
PPARβ/δ is a versatile regulator of distinct biological pro-
cesses including and extending beyond lipid metabolism.
More debatable issue is that whether PPARβ/δ is a potential
regulator of adipocyte diﬀerentiation. In adult mice it com-
prisesanonautonomousdeterminantofadiposity,providing
a plausible link to lipid metabolism. Apart from metabolism,
PPARβ/δ was proposed to be a critical mediator of embryo
implantation. During early development the receptor regu-
lates placentation and is consequently essential for the sur-
vival of most embryos [47].
PPARβ/δ has recently been implicated in hepatic stellate
cell proliferation and liver ﬁbrosis. Hepatic stellate cells be-
come activated in response to liver toxicants, leading to de-
position of extracellular matrix and ﬁbrosis. Ligand activa-
tion of PPARβ/δ enhanced the hepatic stellate cell prolifera-
tion and increased the synthesis of genes associated with the
extracellular matrix leading to hepatic ﬁbrosis [48].
Finally, PPARβ/δ was ascribed an oncogenic function af-
ter being identiﬁed as a direct transcriptional target of β-
catenin. Some studies suggest that activation of PPARβ/δ
is causally associated with polyp formation [49], and that
increased PPARβ/δ expression is required to modulate tar-
get genes that regulate the proliferation of colon tumor cells
[50]. However, current studies clearly show that speciﬁc lig-
and activation of PPARβ/δ leads to the induction of target
gene expression associated with terminal diﬀerentiation of
colonocytes. In contrast to previous reports, PPARβ/δ atten-
uates colon carcinogenesis [51, 52]. Thus, considerable con-
troversyremainsregarding theroleofPPARβ/δ in coloncan-
cer since there is evidence suggesting that PPARβ/δ ligands
couldhaveeitherpositive,negative,oracombinationofboth
eﬀects on colon carcinogenesis.
Activation of PPARβ/δ by an agonist ligand can result
in increased proliferation of breast and prostate cancer cell
lines, as well as endothelial cells, and supports the hypothesis
that PPARβ/δ antagonists might be of therapeutic value in
the management of common epithelial cancers [53].
There is also evidence that PPARβ/δ ligands may inﬂu-
ence skin carcinogenesis. Ligand activation of PPARβ/δ in-
duces terminal diﬀerentiation and an apoptotic-like path-
way in keratinocytes, along with inhibition of cell prolifer-
ation [44]. In addition, PPARβ/δ induces cyclooxygenase-
2 (COX-2) expression in human cholangiocarcinoma cells
and, the COX-2-derived prostaglandin E2 further activates
PPARβ/δ. This positive feedback loop plays an important
role for cholangiocarcinoma cell growth [54] .T h er o l eo f
PPARβ/δ in carcinogenesis is thus unclear and highly con-
troversial.
7. HYPOTHESIS
The ﬁnding that exercise upregulates PPARβ/δ content in
muscle favors a model in which the nuclear receptor plays
a causal role in the increase of oxidative ﬁber number. An-
other common mark of exercise and muscle PPARβ/δ over-
expression is the reduction of body fat content by a decrease
in adipocyte size.
Oxidative myoﬁber remodeling and increase of fatty acid
oxidizing actions of PPARβ/δ in skeletal muscle may give the
expectations of speciﬁc agonists in metabolic syndrome by
limiting substrate availability for lipid synthesis and accu-
mulation in adipose tissue and other insulin sensitive tissues.
PPARβ/δ agonists can drive the formation of oxidative my-
oﬁbersandenhancephysicalactivityendurance.Collectively,
the phenotypes induced by muscle-speciﬁc PPARβ/δ overex-
pression, such as muscle remodeling and reduction of body
fat mass, are highly reminiscent of the adaptive response to
regular physical exercise. Muscle-speciﬁc PPARβ/δ agonist
drugsusedincombinationwithexercisewouldbeakeystrat-
egy to increase physical activity-related energy expenditure
and overcome the sedentary lifestyle and poor cardiorespira-
tory ﬁtness.
Hypothesis is that overexpression and/or overactivity of
muscle-speciﬁc PPARβ/δ by synthetic agonists strongly in-
crease the lipid catabolic activities of skeletal muscle by up-
regulating genes involved in fatty acid burning and also by
stimulating muscle remodeling similar to that promoted by
endurance training. This adaptation may resemble that in-
duced by endurance exercise training. In other words, syn-
thetic activation of muscle PPARβ/δ may simulate partly the
impacts of exercise training even in the absence of training
itself. This strategy obviously could be beneﬁcial to prevent
metabolic disorders, such as insulin resistance, obesity, and
type 2 diabetes. In addition, it is tempting to speculate that
muscle-speciﬁc PPARβ/δ agonists could be expected agents
for the individuals carrying metabolic risk factors who are
in sedentary life style and reluctant to exercise. Finally, most
likelyadverseeﬀectsduetoubiquitousactivationofPPARβ/δ
in the long term may not be seen by the speciﬁc activation of
muscle PPARβ/δ.
8. CONCLUSIONS
PPARβ/δ could be targeted by a speciﬁc agonist in skeletal
muscle in order to prevent metabolic disorders such as in-
sulin resistance and obesity by increasing catabolism of lipid
in muscle and decreasing lipid accumulation in adipose tis-
sue.
The importance of tissue-speciﬁc PPARβ/δ agonism is
obvious because liver-speciﬁc overexpression of this tran-
scription factor may cause glucose intolerance through
the activation of PGC1α. However, speciﬁc activation of
PPARβ/δ in skeletal muscle is very reminiscent of the adap-
tive response to endurance training, which also increases the
levels of PPARβ/δ and PGC1α causing improvements in mi-
tochondrial capacity and insulin sensitivity [25].
Mitochondrial defects are in the very heart of many age-
related disorders but are also present in healthy elderly sub-
jects, resulting in sarcopenia that is a leading cause of dis-
ability in the elderly. Fortunately, even aged muscle is still
very plastic and can respond to proper stimuli by increasing
its mass and strength. The ability of PPARβ/δ to stimulate6 PPAR Research
mitochondrial biogenesis and oxidative function suggests
that the activation of PPARβ/δ could be important for con-
trol of insulin resistance during normal aging. An exciting
expectation for the future use of muscle-speciﬁc PPARβ/δ
agonists might have the potential to not only slow, but also
reverse mitochondrial dysfunction and thereby improve ex-
ercise performance in aging muscle.
Finally, a single bout of exercise can have a very beneﬁcial
eﬀect on glucose metabolism and increase insulin sensitiv-
ity in sedentary subjects. Consequently, main expectation for
the use of PPARβ/δ drugs with the combination of exercise
would be increase physical activity to overcome the seden-
tary lifestyle. However, whatever the research outcomes and
discoveries, probably, the “magic bullet” that promotes def-
inite solutions to disorders in energy metabolism, triggered
by excessive calorie intake and inactivity, does not exist [55].
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